{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T18:07:14Z","timestamp":1749578834204},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,3,28]],"date-time":"2014-03-28T00:00:00Z","timestamp":1395964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immunoblot (IB) techniques using different Epstein\u2013Barr virus (EBV) antigens have been applied for detecting specific antibodies, making possible to obtain EBV seroprofiles in a single determination. The aim of this study was to evaluate a commercial IB for the detection of EBV\u2010specific IgG (Euroimmun, L\u00fcbeck, Germany).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 117 samples classified as EBV primary recent infections (<jats:italic>n<\/jats:italic> = 70), past infections (<jats:italic>n<\/jats:italic> = 29), or not infected (<jats:italic>n<\/jats:italic> = 18) have been used. The samples were characterized by immunofluorescence, by testing EBV capsid antigens IgM and IgG (using indirect approaches) and EBV nuclear antigen (by anticomplement technique; Meridian Bioscience Inc.).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using the cut\u2010off value as defined by the IB manufacturer, the concordance, relative sensitivity, and relative specificity were 85.5 (100\/117), 94.3% (66\/70), and 72.3% (34\/47), respectively. If a corrected cut\u2010off value was considered to classify the samples, the corresponding corrected figures were 89.7, 88.6, and 91.5%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Being a useful serological diagnostic tool, IB for testing EBV IgG seems to be an adequate approach to define EBV seroprofiles. However, efforts to better define the cut\u2010off value should be made in order to improve the performance of the assay in evaluation.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jcla.21726","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T00:41:36Z","timestamp":1396053696000},"page":"47-51","source":"Crossref","is-referenced-by-count":3,"title":["Application of a Commercial Immunoblot to Define EBV IgG Seroprofiles"],"prefix":"10.1002","volume":"29","author":[{"given":"Fernando","family":"de Ory","sequence":"first","affiliation":[{"name":"Laboratory of Serology National Center of Microbiology Institute of Health Carlos III Madrid Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eulalia","family":"Guisasola","sequence":"additional","affiliation":[{"name":"Laboratory of Serology National Center of Microbiology Institute of Health Carlos III Madrid Spain"},{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP) Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tarrag\u00f3","sequence":"additional","affiliation":[{"name":"Laboratory of Serology National Center of Microbiology Institute of Health Carlos III Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Sanz","sequence":"additional","affiliation":[{"name":"CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP) Madrid Spain"},{"name":"Laboratory of Public Health Comunidad de Madrid Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.12.011"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5936.72"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0888-0786(93)90024-T"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.1994.tb00446.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/jcm.31.6.1669-1671.1993","article-title":"Application of low\u2010avidity immunoglobulin G studies to diagnosis of Epstein\u2010Barr virus infectious mononucleosis","volume":"31","author":"Ory F","year":"1993","journal-title":"J Clin Microbiol"},{"key":"e_1_2_5_7_1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1542\/peds.75.6.1011","article-title":"Epstein Barr virus infectious mononucleosis in children. II. Heterophil antibody and viral specific responses","volume":"75","author":"Sumaya CV","year":"1985","journal-title":"Pediatrics"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.8.3381-3387.2004"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00164-09"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(98)00164-5"},{"key":"e_1_2_5_11_1","first-page":"360","article-title":"Understanding interobserver agreement: The kappa statistic","volume":"37","author":"Viera AJ","year":"2005","journal-title":"Fam Med"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00486-10"},{"key":"e_1_2_5_13_1","first-page":"223","article-title":"Simplicity through complexity: Immunoblot with recombinant antigens as the new gold standard in Epstein\u2010Barr virus serology","volume":"47","author":"Bauer G","year":"2001","journal-title":"Clin Lab"},{"key":"e_1_2_5_14_1","first-page":"393","article-title":"Evaluation of three different assays for the assessment of Epstein Barr Virus immunological status","volume":"30","author":"Altuglu I","year":"2007","journal-title":"New Microbiol"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(84)90093-0"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890400215"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.21726","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.21726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T06:33:03Z","timestamp":1696401183000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.21726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/jcla.21726"],"URL":"https:\/\/doi.org\/10.1002\/jcla.21726","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,28]]}}}